[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Alain Kaelin\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":113},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,69,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100360773","phase-3-incobotulinumtoxina-xeomin-to-treat-focal-hand-dystonia-100360773",false,"NCT03977493","IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia","IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia: a Double-blind Placebo-controlled Randomized Multicenter Study: The \"SwissHandSpasm\" Study","Inclusion Criteria:\n\n* Informed Consent as documented by signature\n* Age ≥ 18 years\n* Focal hand dystonia (FHD). Diagnosis must be made by a neurologist specialized in movement disorder (at least 2 years specific training, all partners listed have at least 2 years training)\n* Both idiopathic and secondary FHD are allowed\n* Both drug naive subjects and subjects previously treated with other BoNT-A will be included\n* Patients must be willing and able to comply with the study procedures\n* Female patients of childbearing potential must agree to use an effective method of contraception during the treatment period\n\nExclusion Criteria:\n\n* Presence of spasticity, or other central sensorimotor lesion of motor system other than dystonia in the affected limb\n* Peripheral nerve lesion (diagnosis either clinical or electrophysiological) in the affected limb, for example with a muscle weakness at baseline\n* Contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to BoNT-A toxins including IncobotulinumtoxinA\n* Doses and schedules of any ongoing treatment with potential confounding drugs such as muscle relaxants (for example Tolperison, Tizinadid, Baclofen, Mestinon, Dantrolen), benzodiazepine, neuroleptics or antidepressants have to be kept unchanged throughout the study and no changes should be made between the first trial injection and the end of study visit at week 12.\n* Previous treatment with other BoNT-A less than 3 months before the inclusion in this study\n* Women who are pregnant or breast feeding,\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant\n* Participation in another study with investigational drug within the 30 days preceding and during the present study\n* Previous enrolment into the current study\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons\n* Severe depression (\\>29 as measured with the Beck Depression Inventory, see Appendix 8) or other relevant psychiatric disorder\n* INR \\> 2 on the day of injection if the patient is anticoagulated. If INR \\> 2, the study injection will be delayed until the return to a safer INR.","ALL","18 Years",{"count":19,"type":20},48,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","This study is a multicenter, double-blind, randomized placebo controlled, parallel group, superiority trial in order to test the superiority of intramuscular injections of IncobotulinumtoxinA against placebo using a 1:1 allocation ratio.",[26],"Focal Hand Dystonia","RECRUITING","2026-03-17",{"date":30,"type":31},"2026-03-19","ACTUAL",{"date":33,"type":31},"2018-02-21",{"date":35,"type":20},"2027-12-31",{"name":37,"class":38},"Alain Kaelin","OTHER",5,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},"100600423","empathy-and-self-compassion-in-parkinsons-disease-patients-and-caregivers-100600423","NCT07097298","Empathy and (Self-)Compassion in Parkinson's Disease Patients and Caregivers","Empathy and (Self-)Compassion to Improve the Quality of Life of Parkinson's Disease Patients and Caregivers: an Exploratory Study","Inclusion Criteria:\n\n* Diagnosis of PD\n* Hoehn and Yahr scale, stage ≤ 3\n* Mini Mental State Examination with a score ≥ 26\n* Able to give informed consent as documented by signature\n* At least, secondary school education\n* To have a regular caregiver at home\n\nExclusion Criteria:\n\n* Any medical condition that is not PD, such as drug induced parkinsonism\n* Major depression, dysthymia, or according to DSM-V\n* Other neurological or psychiatric diseases\n* Neuropsychological scores compatible with the diagnosis of early dementia\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, etc\n\nFor CAREGIVERS:\n\nInclusion criteria\n\n* Taking care of the patient on a regular basis, i.e., at least 3 days per week\n* Being caregiver of the patients for at least 3 months\n* At least, secondary school education\n* Written informed consent","50 Years","80 Years",{"count":50,"type":20},30,[52],"NA","The goal of this clinical trial is to improve quality of life in Parkinson's Disease (PD) patients by increasing their empathy and their (self-)compassion. The main question it aims to answer is:\n\nDoes the level of quality of life in PD patients and caregivers improve after empathy\u002F(self-)compassion training?\n\nParticipants will be delivered a 6-week empathy and compassion training (mindfulness, writing and poetry exercises addressing the cognitive, emotional, motivational and behavioural components of (self-)compassion) and will also be asked to answer questionnaires before and after the training",[55],"Parkinson Disease(PD)",[57,58,59],"Empathy","(self-)compassion","Parkinson disease (PD)","2025-11-24",{"date":62,"type":31},"2025-12-01",{"date":64,"type":31},"2025-11-06",{"date":66,"type":20},"2027-07",{"name":37,"class":38},1,{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":68},"100560971","technical-and-clinical-validation-of-the-wpm-semg-prototype-100560971","NCT06584084","Technical and Clinical Validation of the WPM-SEMG Prototype","Technical and Clinical Validation Study of a New Wireless Portable and Multi-Channel Surface EMG Device to Analyse Motor Unit Action Potentials","Eligibility criteria for healthy volunteers\n\n* Inclusion Criteria\n\n  * Healthy volunteers\n  * Female or male\n  * 18 years or older\n  * Preserved cognitive capacity\n  * Ability to understand the study\n  * Willingness to complete all the study assessments\n  * No chronic or concomitant use of medications or treatment\n  * Written informed consent\n* Exclusion Criteria\n\n  * Skin lesions in the area below the electrode\n  * Allergy to metal alloys\n  * History of skin disease\n  * Pregnancy\n  * Lactation\n  * Known causes of neuromuscular disease\n  * Inability to follow the procedures of the study\n\nEligibility criteria for patients\n\n* Inclusion Criteria\n\n  * Patients of the Neurocentro della Svizzera Italiana with diagnosis of myopathy or neuropathy that requires a needle-EMG electrophysiological testing as standard clinical management of the disease\n  * Female or male\n  * 18 years or older\n  * Preserved cognitive capacity\n  * Ability to understand the study\n  * Willingness to complete all the study assessments\n  * No chronic or concomitant use of medications or treatment that may influence the measure in the opinion of the investigator (muscle relaxant such as baclofen, statin, benzodiazepine).\n  * Written informed consent\n* Exclusion Criteria\n\n  * Skin lesions in the area below the electrode\n  * Allergy to metal alloys\n  * History of skin disease\n  * Cognitive and\u002For psychiatric disorders\n  * Pregnancy\n  * Lactation\n  * Neuromuscular disease other than myopathy and neuropathy\n  * Inability to follow the procedures of the study",true,{"count":78,"type":20},70,[52],"Validation study designed to demonstrate the technical and clinical performance, and the safety of a new medical device in healthy volunteers and patients with myopathy or neuropathy. The medical device is the WPM-SEMG prototype designed for recording electrophysiological signals of muscles.",[82],"Neuron Disease, Motor","2024-09-04",{"date":85,"type":31},"2024-09-19",{"date":87,"type":31},"2018-01-19",{"date":89,"type":20},"2026-04-30",{"name":37,"class":38},{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":76,"sex":16,"minAge":17,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":21,"phases":101,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":68},"100504558","clinical-relevance-of-the-hd-semg-signals-in-the-post-stroke-rehabilitation-100504558","NCT05849896","Clinical Relevance of the HD sEMG Signals in the Post-stroke Rehabilitation","Assistance and Evaluation of the Post-stroke Rehabilitation Process Via the Analysis of High-Density Surface EMG Signals Acquired With the WPM-SEMG-V2 Device: A Single Centre, Prospective, Feasibility Investigation in Healthy Volunteers and Post-stroke Patients","Inclusion Criteria:\n\nHealthy volunteers\n\n* Written Informed Consent\n* Female or male\n* 18 years or older\n* Ability to understand the investigation\n* Willingness to complete all the investigation assessments\n* Ability to perform the procedures of the investigation\n* Ability to perform maximal voluntary muscle extension of the target muscle and limb\n\nAdditional inclusion criteria only for the recreationally active or athletic, healthy volunteers :\n\n* Subjects who participated in at least 150 min of moderate activity per week over the last six months.\n* between 18 and 20 years (preferably)\n\nPost-stroke patients\n\n* Written informed consent\n* Female or male\n* 18 years or older\n* Have a first-time stroke\n* Ability to perform maximal voluntary muscle extension of the target muscle and limb\n* Preserved cognitive capacity to perform the task\n* Ability to understand the investigation\n* Willingness to complete all the investigation assessments\n* Ability to perform the procedures of the investigation\n\nExclusion Criteria:\n\nHealthy volunteers\n\n* Any significant acute disease state\n* Skin disorders\u002Fallergies at the site of contact with the investigational device\n* History of skin disease\n* Known hypersensitivity or allergy to component of the investigational product (e.g. metal alloys) or other materials used (e.g., abrasive gel, foam with polystyrene markers)\n* Chronic use of medications or treatment\n\nPost-stroke patients\n\n* History of spinal cord injury or traumatic brain damage\n* Serious medical illness that precludes performing the task\n* Severe locomotion disorder due to other causes\n* Severe neurological disease other than stroke\n* Any significant acute disease state\n* Skin disorders\u002Fallergies at the site of contact with the investigational device\n* History of skin disease\n* Known hypersensitivity or allergy to component of the investigational product (e.g. metal alloys) or other materials used (e.g., abrasive gel, foam with polystyrene markers)","99 Years",{"count":100,"type":20},40,[52],"The goal of this clinical trial is to learn about the WPM-SEMG-V2 device (Wireless Portable and Multi-Channel, WPM) designated to acquire high-density (HD) surface electromyography (sEMG) signals in healthy volunteers and post-stroke patients. The main objectives are: 1) to technically and clinically validate the WPM-SEMG-V2 device in healthy volunteers; 2) to demonstrate the clinical relevance of the HD sEMG signals to support the process of rehabilitation of post-stroke patients. Participants will be asked to perform simple exercises using the muscles of the hand or the leg in static or dynamic contractions while wearing the WPM-SEMG-V2 device.",[104],"Stroke","2024-09-02",{"date":107,"type":31},"2024-09-05",{"date":109,"type":31},"2023-03-13",{"date":111,"type":20},"2026-04",{"name":37,"class":38},""]